Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI-46 PET/CT for Liver Fibrosis in NASH
NCT06160271Phase 2Not yet recruiting
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of 68Ga FAPI-46 in Nonalcoholic steatohepatitis (NASH), sponsored by CHRU de Nancy - Hôpital Central. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
68Ga FAPI-46
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06160271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06160271.